Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark.
Fam Cancer. 2013 Sep;12(3):567-72. doi: 10.1007/s10689-013-9601-7.
We tested the hypothesis that splice site variations in MSH2 and MLH1 are associated with increased risk of hereditary non-polyposis colorectal cancer (HNPCC) and of cancer in general in the general population. In a cohort of 154 HNPCC patients with sequenced MSH2 and MLH1, we identified four possible splice-site mutations, which we subsequently genotyped in more than 9,000 individuals from the general population. Allele frequencies in the general population were 0 % for 942+3A>T in MSH2, 0.05 % for 307-19A>G, 0.005 % for 1,667+(2-8)del(taaatca);ins(attt), and 4.4 % for 1039-8T>A in MLH1. Odds ratios for HNPCC in a case-control design were 419 (95 % CI: 53-18,900) for 942+3A>T in MSH2, 19 (5-72) for 307-19A>G, 194 (21-1,768) for 1,667+(2-8)del(taaatca); ins(attt), and 0.3 (0.1-0.7) for 1,039-8T>A in MLH1. In the general population, incidence rate ratios for 1,039-8T>A carriers versus noncarriers were 0.70 (0.51-0.96) for HNPCC-related cancers combined and 0.82 (0.71-0.94) for all cancers combined in a prospective design. The three rare mutations were associated with increased risk of HNPCC. In contrast, the more common 1,039-8T>A associated with a decreased risk of HNPCC, of HNPCC-related cancers and of all cancers combined in the general population. These findings are novel and important in the counseling of HNPCC patients and their relatives.
我们验证了这样一个假说,即 MSH2 和 MLH1 的剪接位点变异与遗传性非息肉病性结直肠癌(HNPCC)风险增加以及一般人群中癌症风险增加相关。在一组经过 MSH2 和 MLH1 测序的 154 名 HNPCC 患者中,我们发现了四个可能的剪接位点突变,随后在一般人群中的 9000 多人中进行了基因分型。一般人群中 MSH2 的 942+3A>T 的等位基因频率为 0%,307-19A>G 的为 0.05%,1,667+(2-8)del(taaatca);ins(attt) 的为 0.005%,MLH1 的 1039-8T>A 的为 4.4%。病例对照设计中 HNPCC 的比值比为 MSH2 的 942+3A>T 为 419(95%CI:53-18900),307-19A>G 的为 19(5-72),1,667+(2-8)del(taaatca);ins(attt) 的为 194(21-1768),MLH1 的 1039-8T>A 的为 0.3(0.1-0.7)。在一般人群中,1039-8T>A 携带者与非携带者的发病率比为 HNPCC 相关癌症的 0.70(0.51-0.96),前瞻性设计中所有癌症的 0.82(0.71-0.94)。这三种罕见突变与 HNPCC 风险增加相关。相比之下,更为常见的 1039-8T>A 与 HNPCC、HNPCC 相关癌症和一般人群中所有癌症的风险降低相关。这些发现对于 HNPCC 患者及其亲属的咨询具有新颖性和重要性。